These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34470483)

  • 1. Atherogenic Dyslipidemia and Residual Vascular Risk After Stroke or Transient Ischemic Attack.
    Hoshino T; Ishizuka K; Toi S; Mizuno T; Nishimura A; Takahashi S; Wako S; Kitagawa K
    Stroke; 2022 Jan; 53(1):79-86. PubMed ID: 34470483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients.
    Sirimarco G; Labreuche J; Bruckert E; Goldstein LB; Fox KM; Rothwell PM; Amarenco P;
    Stroke; 2014 May; 45(5):1429-36. PubMed ID: 24736236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triglyceride-glucose index as a prognostic marker after ischemic stroke or transient ischemic attack: a prospective observational study.
    Hoshino T; Mizuno T; Ishizuka K; Takahashi S; Arai S; Toi S; Kitagawa K
    Cardiovasc Diabetol; 2022 Nov; 21(1):264. PubMed ID: 36451149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Role of Hypertriglyceridemia in Patients With Stroke of Atherothrombotic Origin.
    Hoshino T; Ishizuka K; Toi S; Mizuno T; Nishimura A; Wako S; Takahashi S; Kitagawa K
    Neurology; 2022 Apr; 98(16):e1660-e1669. PubMed ID: 35296551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atherogenic dyslipidemia in patients with transient ischemic attack.
    Sirimarco G; Deplanque D; Lavallée PC; Labreuche J; Meseguer E; Cabrejo L; Guidoux C; Olivot JM; Abboud H; Lapergue B; Klein IF; Mazighi M; Touboul PJ; Bruckert E; Amarenco P
    Stroke; 2011 Aug; 42(8):2131-7. PubMed ID: 21737806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-Density Lipoprotein Cholesterol and Risk of Recurrent Vascular Events in Chinese Patients With Ischemic Stroke With and Without Significant Atherosclerosis.
    Lau KK; Chua BJ; Ng A; Leung IY; Wong YK; Chan AH; Chiu YK; Chu AX; Leung WCY; Tsang AC; Teo KC; Mak HK
    J Am Heart Assoc; 2021 Aug; 10(16):e021855. PubMed ID: 34369170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between atherogenic dyslipidemia and recurrent stroke risk in patients with different subtypes of ischemic stroke.
    Zhao L; Wang R; Song B; Tan S; Gao Y; Fang H; Lu J; Xu Y
    Int J Stroke; 2015 Jul; 10(5):752-8. PubMed ID: 25924059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guideline-directed low-density lipoprotein management in high-risk patients with ischemic stroke: findings from Get with the Guidelines-Stroke 2003 to 2012.
    Saposnik G; Fonarow GC; Pan W; Liang L; Hernandez AF; Schwamm LH; Smith EE;
    Stroke; 2014 Nov; 45(11):3343-51. PubMed ID: 25300975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidized Low-Density Lipoprotein to High-Density Lipoprotein Ratio Predicts Recurrent Stroke in Minor Stroke or Transient Ischemic Attack.
    Wang A; Li S; Zhang N; Dai L; Zuo Y; Wang Y; Meng X; Wang Y
    Stroke; 2018 Nov; 49(11):2637-2642. PubMed ID: 30355199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of atherogenic dyslipidemia for predicting cardiovascular risk in patients with angiographically defined coronary artery disease.
    Arca M; Montali A; Valiante S; Campagna F; Pigna G; Paoletti V; Antonini R; Barillà F; Tanzilli G; Vestri A; Gaudio C
    Am J Cardiol; 2007 Nov; 100(10):1511-6. PubMed ID: 17996510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of atherosclerosis on 5-year risk of major vascular events in patients with transient ischaemic attack or minor ischaemic stroke: an international prospective cohort study.
    Lavallée PC; Charles H; Albers GW; Caplan LR; Donnan GA; Ferro JM; Hennerici MG; Labreuche J; Molina C; Rothwell PM; Steg PG; Touboul PJ; Uchiyama S; Vicaut É; Wong LKS; Amarenco P;
    Lancet Neurol; 2023 Apr; 22(4):320-329. PubMed ID: 36931807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.
    Roe MT; Li QH; Bhatt DL; Bittner VA; Diaz R; Goodman SG; Harrington RA; Jukema JW; Lopez-Jaramillo P; Lopes RD; Louie MJ; Moriarty PM; Szarek M; Vogel R; White HD; Zeiher AM; Baccara-Dinet MT; Steg PG; Schwartz GG
    Circulation; 2019 Nov; 140(19):1578-1589. PubMed ID: 31475572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. More Than 50 Percent Reduction in LDL Cholesterol in Patients With Target LDL <70 mg/dL After a Stroke.
    Amarenco P; Lavallée PC; Kim JS; Labreuche J; Charles H; Giroud M; Lee BC; Mahagne MH; Meseguer E; Nighoghossian N; Steg PG; Vicaut É; Bruckert E;
    Stroke; 2023 Aug; 54(8):1993-2001. PubMed ID: 37376989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What Proportion of Patients Admitted with Stroke or Transient Ischemic Attack May Be Suitable for Newer Cholesterol-Lowering Treatment?
    Alakbarzade V; Pereira AC
    J Stroke Cerebrovasc Dis; 2020 Jan; 29(1):104457. PubMed ID: 31732461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Amarenco P; Goldstein LB; Callahan A; Sillesen H; Hennerici MG; O'Neill BJ; Rudolph AE; Simunovic L; Zivin JA; Welch KM;
    Atherosclerosis; 2009 Jun; 204(2):515-20. PubMed ID: 18962621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desirable Low-Density Lipoprotein Cholesterol Levels for Preventing Stroke Recurrence: A Post Hoc Analysis of the J-STARS Study (Japan Statin Treatment Against Recurrent Stroke).
    Hosomi N; Kitagawa K; Nagai Y; Nakagawa Y; Aoki S; Nezu T; Kagimura T; Maruyama H; Origasa H; Minematsu K; Uchiyama S; Matsumoto M;
    Stroke; 2018 Apr; 49(4):865-871. PubMed ID: 29511130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol.
    Lawler PR; Akinkuolie AO; Chu AY; Shah SH; Kraus WE; Craig D; Padmanabhan L; Glynn RJ; Ridker PM; Chasman DI; Mora S
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28733430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperhomocysteinemia Increases Vascular Risk in Stroke Patients with Chronic Kidney Disease.
    Mizuno T; Hoshino T; Ishizuka K; Toi S; Takahashi S; Wako S; Arai S; Kitagawa K
    J Atheroscler Thromb; 2023 Sep; 30(9):1198-1209. PubMed ID: 36436876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diastolic Dysfunction as a Positive Predictor of Recurrent Vascular Events in Patients With Noncardioembolic Stroke.
    Ishizuka K; Hoshino T; Mizuno T; Takahashi S; Wako S; Arai S; Toi S; Kitagawa K
    Stroke; 2024 Mar; 55(3):595-603. PubMed ID: 38328918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.